Asceneuron

Asceneuron is a clinical-stage biotechnology company focused on developing orally bioavailable therapies to treat debilitating neurodegenerative diseases with significant unmet medical needs. The company's lead product, ASN120290, has received orphan drug designation from the FDA for progressive supranuclear palsy (PSP), a rapidly progressing rare neurodegenerative disease that causes severe issues with walking, balance, speech, swallowing, and vision due to the accumulation of tau protein aggregates in the brain. The company is also developing a next-generation O-GlcNAcase inhibitor, ASN51, targeting Alzheimer’s disease and related conditions.